(Total Views: 628)
Posted On: 02/08/2023 7:12:49 PM
Post# of 85943
Now that news checks out 1000% factual. Nice find MLR re IR Med & Dr. Dalton !! $$ #Kaboom #boomshakalaka
Announcing an Advisory Board Member: As the company shifts toward its first sales approach, IR-Med strengthened its corporate and advisory team by announcing Dr. David Dalton to its Scientific Advisory Board. He is a hall of fame CEO, entrepreneur, pharmaceutical executive and founder of over 40 companies. In his role, Dr. Dalton will support IR-Med with analyzing the benefits of the PressureSafe device for Hispanic and African American populations in the United States, two groups that suffer from pressure wounds nearly twice as much as the Caucasian population due to late diagnosis.
Raising Additional Funds: In late 2022, the company completed a private placement with gross proceeds totaling $3.6M. To date, the total investment in the company is just over $9M.
Looking ahead to 2023, IR-Med expects to submit the PressureSafe device for FDA approval during the second half of the year and to move forward with the development of the Nobiotics device. The company is also planning to expand usability studies for the PressureSafe device to in both leading Israeli and U.S. hospitals.
For more information on the company or its PressureSafe device, please visit https://www.ir-medical.com/.
Announcing an Advisory Board Member: As the company shifts toward its first sales approach, IR-Med strengthened its corporate and advisory team by announcing Dr. David Dalton to its Scientific Advisory Board. He is a hall of fame CEO, entrepreneur, pharmaceutical executive and founder of over 40 companies. In his role, Dr. Dalton will support IR-Med with analyzing the benefits of the PressureSafe device for Hispanic and African American populations in the United States, two groups that suffer from pressure wounds nearly twice as much as the Caucasian population due to late diagnosis.
Raising Additional Funds: In late 2022, the company completed a private placement with gross proceeds totaling $3.6M. To date, the total investment in the company is just over $9M.
Looking ahead to 2023, IR-Med expects to submit the PressureSafe device for FDA approval during the second half of the year and to move forward with the development of the Nobiotics device. The company is also planning to expand usability studies for the PressureSafe device to in both leading Israeli and U.S. hospitals.
For more information on the company or its PressureSafe device, please visit https://www.ir-medical.com/.
(10)
(1)
https://www.youtube.com/watch?v=V-OYKd8SVrI
I do my own dd. My opinions are simply my opinions. Please do your own research before investing in any stock.
I do my own dd. My opinions are simply my opinions. Please do your own research before investing in any stock.
Scroll down for more posts ▼
